BioMarin Pharmaceutical Inc. $BMRN Stock Holdings Decreased by Vanguard Personalized Indexing Management LLC

Key Points

• Vanguard Personalized Indexing Management LLC has reduced its stake in BioMarin Pharmaceutical by 42.7% in the second quarter, selling 10,433 shares to hold a total of 13,993 shares valued at approximately $769,000.
• BioMarin has seen various institutional investors adjusting their holdings, with 98.71% of the company's stock owned by institutional investors, highlighting significant interest in the company.
• Analysts have mixed ratings for BioMarin, with one firm lowering the stock from a "strong-buy" to a "hold," while others maintain "buy" and "outperform" ratings, indicating varied confidence in its performance going forward.

Vanguard Personalized Indexing Management LLC lowered its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 42.7% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 13,993 shares of the biotechnology company's stock after selling 10,433 shares during the period. Vanguard Personalized Indexing Management LLC's holdings in BioMarin Pharmaceutical were worth $769,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Byrne Financial Freedom LLC increased its position in shares of BioMarin Pharmaceutical by 4.4% in the 1st quarter. Byrne Financial Freedom LLC now owns 3,852 shares of the biotechnology company's stock worth $272,000 after purchasing an additional 161 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. increased its position in shares of BioMarin Pharmaceutical by 0.9% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 22,523 shares of the biotechnology company's stock worth $1,592,000 after purchasing an additional 197 shares during the last quarter. Xponance Inc. increased its position in shares of BioMarin Pharmaceutical by 0.6% in the 1st quarter. Xponance Inc. now owns 31,877 shares of the biotechnology company's stock worth $2,253,000 after purchasing an additional 202 shares during the last quarter. Farther Finance Advisors LLC increased its position in shares of BioMarin Pharmaceutical by 95.9% in the 1st quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 211 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of BioMarin Pharmaceutical by 5.0% in the 1st quarter. Nisa Investment Advisors LLC now owns 4,572 shares of the biotechnology company's stock valued at $323,000 after buying an additional 217 shares during the period. Institutional investors own 98.71% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Zacks Research lowered shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Wedbush reaffirmed an "outperform" rating and issued a $94.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, August 5th. Wall Street Zen lowered shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, October 11th. Guggenheim lifted their price target on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Finally, Wolfe Research set a $95.00 price target on shares of BioMarin Pharmaceutical and gave the company an "outperform" rating in a report on Tuesday, July 15th. Thirteen analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, BioMarin Pharmaceutical presently has an average rating of "Moderate Buy" and an average price target of $93.26.

BioMarin Pharmaceutical Trading Down 0.4%

BioMarin Pharmaceutical stock opened at $53.07 on Tuesday. The firm has a 50-day moving average price of $55.58 and a two-hundred day moving average price of $57.37. The firm has a market capitalization of $10.19 billion, a price-to-earnings ratio of 15.75, a PEG ratio of 0.67 and a beta of 0.33. BioMarin Pharmaceutical Inc. has a 52-week low of $51.56 and a 52-week high of $73.51. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.